Fenretinide
Names | |
---|---|
IUPAC name
N-(4-Hydroxyphenyl)retinamide
| |
Systematic IUPAC name
(2E,4E,6E,8E)-N-(4-Hydroxyphenyl)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraenamide | |
Identifiers | |
3D model (
JSmol ) |
|
ChEMBL | |
ChemSpider | |
DrugBank | |
ECHA InfoCard
|
100.164.069 |
KEGG | |
MeSH | Fenretinide |
PubChem CID
|
|
UNII | |
CompTox Dashboard (EPA)
|
|
| |
| |
Properties | |
C26H33NO2 | |
Molar mass | 391.546 g/mol |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
Fenretinide (N-(4-hydroxyphenyl)retinamide; 4-HPR) (
In cancer studies, Fenretinide treatment may cause ceramide (a wax-like substance) to build up in tumor cells and is associated with the accumulation of reactive oxygen species (ROS), resulting in cell death through apoptosis and/or necrosis.[3] Fenretinide accumulates preferentially in fatty tissue such as the breast, which may contribute to the effectiveness of fenretinide against breast cancer.[4][5] Phase III clinical trial data has suggested that fenretinide reduces breast cancer relapse in pre-menopausal women.[6] Common side effects associated with fenretinide treatment include skin dryness and night-blindness, which is reversible upon cessation of treatment. Specific types of cancer under investigation include or have included ovarian, prostate, cervical, lung, renal, bladder, breast, glioma, skin, head and neck carcinoma, non-Hodgkin's lymphoma, neuroblastoma, and Ewing's sarcoma.[citation needed]
References
External links
- Numerous references and links to current and past clinical trials and studies of fenretinide can be found at the Journal of Clinical Oncology website